The Straits TimesHealth
US regulator rejects closely watched China lung cancer drug

The United States Food and Drug Administration has rejected ivonescimab, a closely watched lung cancer treatment developed in China. The decision puts a high-profile drug in the spotlight as China’s pharmaceutical industry gains prominence in global drug development.
This card is an AI-assisted summary of reporting published by The Straits Times. Read the original report before relying on it for medical, legal, financial, safety, or emergency decisions.